DCGI approved India’s first intra-nasal COVID-19 vaccine for restricted emergency use

  • The Drug Controller General of India (DCGI) on 6th September approved the country’s first intra-nasal COVID-19 vaccine – Bharat Biotech’s iNCOVACC, for restricted emergency use in people above the age of 18 years.
  • Health and Family Welfare Minister Dr. Mansukh Mandaviya has described this achievement as a big boost in India’s fight against COVID-19.
  • Dr. Mansukh Mandaviya informed that Bharat Biotech’s Recombinant Nasal Vaccine has been approved by Central Drugs Standard Control Organization (CDSCO) for restricted use in emergency situation for primary immunization in above 18 years age group.

Leave a Comment

Your email address will not be published.